P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY

The endothelial adhesion protein mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is a promising novel drug target. The fully human IgG2 anti-MAdCAM-1 monoclonal antibody SHP647 is in development for the treatment of Crohn’s disease (CD).